EGFR and lung adenocarcinoma: In conclusion, this study confirmed that the 3rd generation EGFR-TKI osimertinib has a strong tumor suppressive effect on lung adenocarcinoma transplanted tumor through cell experiment and animal experiment of transplanted tumor.